Abbott Labs Poised to Weather Market Storm with 54-Year Dividend Streak

With the stock market trading near record highs and geopolitical issues causing uncertainty, investors are wondering if a painful sell-off is overdue. If it is, Abbott Laboratories (ABT) could provide a stable income stream to help soften the blow.

As a Dividend King, Abbott has raised its dividend for 54 consecutive years, making it an attractive option for investors seeking a steady income source. The company's latest results show that it can support future payouts, with sales up 13% year over year and adjusted diluted earnings per share (EPS) beating Wall Street expectations.

Abbott's dividend payout ratio is around 46%, meaning the company pays out less than half of its earnings as dividends. This leaves room to reinvest in the business, which could support future growth and dividend increases. The stock's forward dividend yield is roughly 2.3%, making it an attractive option for income-seeking investors.

Management believes that sales and earnings will accelerate in the second half of 2026, driven by new products and a major deal. The acquisition of Exact Sciences has expanded Abbott's presence in the fast-growing cancer diagnostics market, with revenue growing 13.3% in the second quarter. Analysts are bullish on the stock, with an average 'strong buy' rating.